TABLE 1.

Summary for standards, lobeline, lobelane, and N-1,2-diol analogs

Compound	Ki ± S.E.M.
	DAT, [3H]DA Uptake	SERT, [3H]5-HT Uptake	VMAT2, [3H]DTBZ Binding	VMAT2, [3H]DA Uptake
	μM
Standards
GBR 12909	0.0009 ± 0.0001a	N.D.	N.D.	N.D.
Cocaine	0.48 ± 0.07	N.D.	N.D.	N.D.
Fluoxetine	N.D.	0.007 ± 0.0001a	N.D.	N.D.
Ro-4-1284	0.04 ± 0.005	0.02 ± 0.003	0.03 ± 0.003a	0.02 ± 0.002a
Lobeline, lobelane, and N-1,2-diol analogs
Lobeline	28.2 ± 6.73	46.8 ± 3.70	2.04 ± 0.64b	1.27 ± 0.46
Lobelane	1.05 ± 0.03	3.60 ± 0.35	0.97 ± 0.19b	0.067 ± 0.007
GZ-745A	0.60 ± 0.06	8.43 ± 2.80	0.56 ± 0.08	0.19 ± 0.05
GZ-745B	1.08 ± 0.12	11.0 ± 3.12	1.28 ± 0.13	0.86 ± 0.12
N-1,2-Diol analogs containing 1-naphthyl or 4-biphenyl substituents
GZ-794A	1.43 ± 0.14	0.31 ± 0.08	0.31 ± 0.07	0.033 ± 0.002
GZ-794B	1.57 ± 0.16	0.16 ± 0.04	0.13 ± 0.01	0.08 ± 0.01
GZ-796A	8.33 ± 1.46	5.30 ± 0.96	>100	0.79 ± 0.23
GZ-796B	3.43 ± 0.63	2.55 ± 0.77	90.2 ± 9.70	2.25 ± 1.30
N-1,2-Diol analogs containing aromatic methoxy or methylene-dioxy substituents
GZ-790A	3.80 ± 0.69	3.14 ± 1.18	0.46 ± 0.22	0.14 ± 0.02
GZ-790B	6.67 ± 2.15	8.03 ± 2.30	2.73 ± 0.68	0.52 ± 0.04
GZ-792A	2.90 ± 0.23	1.33 ± 0.46	1.04 ± 0.73	0.49 ± 0.06
GZ-792B	4.77 ± 1.03	0.94 ± 0.14	1.87 ± 0.69	0.79 ± 0.08
GZ-793A	1.44 ± 0.27	9.36 ± 2.74	8.29 ± 2.79	0.029 ± 0.008
GZ-793B	3.40 ± 0.82	10.4 ± 2.75	7.74 ± 2.34	0.18 ± 0.04
GZ-797A	2.46 ± 0.16	2.10 ± 0.70	1.30 ± 0.05	0.16 ± 0.04
GZ-797B	2.21 ± 0.31	2.63 ± 0.60	5.61 ± 0.62	0.76 ± 0.04
N-1,2-Diol analogs containing aromatic halogeno substituents
GZ-791A	0.25 ± 0.07	1.32 ± 0.46	1.00 ± 0.16	0.19 ± 0.06
GZ-791B	0.62 ± 0.05	2.87 ± 0.50	1.08 ± 0.38	1.03 ± 0.16
GZ-795A	3.87 ± 0.89	2.15 ± 0.38	10.4 ± 0.65	0.14 ± 0.04
GZ-795B	9.50 ± 2.53	1.86 ± 0.39	13.9 ± 0.38	0.09 ± 0.04

N.D., not determined.

^a n = 3–4 rats.

^b Data for [³H]DTBZ binding for lobeline and lobelane taken from Nickell et al., 2010.